Table 2.
Viral load (VL) and drug resistance mutation (DRM) distribution in patients in virological failure (VF) according to treatment duration
| Senegal | ||||
|---|---|---|---|---|
|
|
||||
| Treatment duration | M6–M12 | M13–M24 | >M24 | Total |
| Sample size | 26 | 23 | 70 | 119 |
| VF (VL>3log10 copies/mL) | 5 | 9 | 17 | 31 |
| VF (VL>3.7log10 copies/mL) | 3 | 4 | 7 | 14 |
| Genotyped | 4 | 7 | 16 | 27 |
| Any DRM | 1 | 4 | 14 | 19 |
| No DRM | 3 | 3 | 2 | 8 |
| Mali | ||||
| Sample size | 22 | 27 | 103 | 152 |
| VF (VL>3log10 copies/mL) | 1 | 3 | 12 | 16 |
| VF (VL>3.7log10 copies/mL) | 0 | 3 | 7 | 10 |
| Genotyped | 1 | 3 | 11 | 15 |
| Any DRM | 1 | 3 | 10 | 14 |
| No DRM | 0 | 0 | 1 | 1 |
| Guinea-Conakry | ||||
| Sample size | 13 | 31 | 92 | 136 |
| VF (VL>3log10 copies/mL) | 4 | 7 | 22 | 33 |
| VF (VL>3.7log10 copies/mL) | 2 | 2 | 11 | 15 |
| Genotyped | 4 | 5 | 19 | 28 |
| Any DRM | 3 | 2 | 14 | 19 |
| No DRM | 1 | 3 | 5 | 9 |